Finance

Beta
Lists
SZD:FRA
Santen Pharmaceutical Co Ltd
€9.90
+0.51%
(+0.050) 1D
Jun 4, 8:02:28 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for SZD...
Open
€9.90
High
€9.90
Low
€9.90
Mkt. cap
603.33B
Avg. vol.
0.00
Volume
0.00
52-wk high
€10.30
52-wk low
€8.05
No. of employees
4K
Open
€9.90
High
€9.90
Low
€9.90
Mkt. cap
603.33B
Avg. vol.
0.00
Volume
0.00
52-wk high
€10.30
52-wk low
€8.05
No. of employees
4K
News stories
From sources across the web
Profile
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established. In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products. Wikipedia
About Santen Pharmaceutical Co Ltd
CEOAkira Kurokawa | Shigeo Taniuchi
Employees3.85K
Founded1890
HeadquartersOsaka, Kansai, Japan
SectorPharmaceutical industry
Websitesanten.com
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
68.74B
69.14B
72.88B
80.86B
Cost of goods sold
31.62B
29.06B
32.14B
29.07B
Cost of revenue
31.62B
29.06B
32.14B
29.07B
Research and development expenses
6.21B
6.16B
6.00B
7.81B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.20B
21.31B
22.27B
24.79B
Operating expense
29.54B
29.74B
30.45B
32.21B
Total operating expenses
61.16B
58.80B
62.58B
61.28B
Operating income
7.57B
10.34B
10.30B
19.58B
Other non operating income
-1.00M
-
2.00M
-2.00M
EBT including unusual items
7.45B
10.18B
10.44B
19.37B
EBT excluding unusual items
7.45B
10.18B
10.44B
19.37B
Income tax expense
1.59B
2.19B
2.30B
3.80B
Effective tax rate
21.30%
21.53%
22.00%
19.64%
Other operating expenses
-42.00M
-6.00M
-28.00M
-2.51B
Net income
5.88B
8.06B
7.88B
15.55B
Net profit margin
8.55%
11.66%
10.81%
19.23%
Earnings per share
-
-
-
-
Interest and investment income
627.00M
257.00M
455.00M
300.00M
Interest expense
-749.00M
-415.00M
-318.00M
-512.00M
Net interest expenses
-122.00M
-158.00M
137.00M
-212.00M
Depreciation and amortization charges
-
-2.18B
-
-6.65B
EBITDA
12.07B
15.03B
14.92B
24.13B
Gain or loss from assets sale
-
-
-
3.84B
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer